Company Overview and News

‘White knight’s rescue from PN17 not needed’

2018-06-12 theedgemarkets
PETALING JAYA: Oil and gas company Daya Materials Bhd says it has no need for a white knight to help the company exit its Practice Note 17 (PN17) status, which it triggered in February this year.

KLCI to trend sideways, automotive stocks to be in focus

2018-06-11 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI is expected to trend sideways today, with automotive-related stocks possibly in focus.
6173 5209 SRE 0091 0043

Sapura Energy, RHB, Bina Darulaman, Daya Materials, Metronic Global, Meda Inc and Gas Malaysia

2018-06-11 theedgemarkets
KUALA LUMPUR (June 11): Based on corporate announcements and news flow today, companies in focus on Tuesday (June 12) may include: Sapura Energy Bhd, RHB Bank Bhd, Bina Darulaman Bhd, Daya Materials Bhd, Metronic Global Bhd, Meda Inc Bhd and Gas Malaysia Bhd.
4634 6173 5209 0091 BSMAF 0043 7078 1818

Daya Materials plans to submit regularisation plan by August this year

2018-06-11 theedgemarkets
PETALING JAYA (June 11): Practice Note 17 company Daya Materials Bhd plans to submit its regularisation plan to Bursa Malaysia by August this year.
0091 BSMAF 1818

The Week Ahead: Eyes on Trump-Kim rendezvous, FOMC hike, full Cabinet line-up and World Cup 2018

2018-06-11 theedgemarkets
The world will be watching two of the greatest shows this week — the momentous meeting between US President Donald Trump and North Korean leader Kim Jong-un at the Capella Hotel in Singapore on June 12, and the kick-off of the 2018 Fifa World Cup in Moscow on Thursday, just ahead of the Hari Raya celebrations on Friday.
9717 5216 1201 3921 0091 CPICQ FUTR 5085 0151 8311 0152 LIIHF

Trading ideas: Kerjaya Prospek, AWC, Ekovest, AirAsia, Daya Materials

KUALA LUMPUR: Kerjaya Prospek Group Bhd , AWC Bhd, Ekovest Bhd , AirAsia Group Bhd and Daya Materials Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.

Daya Materials in provision deal with Schlumberger

PETALING JAYA: Daya Materials Bhd has entered into a master agreement with Schlumberger Logelco Inc for the provision of non-explosive radial cutting torch, perforating torch cutter, and related energetic and thermite-based solutions services.
0091 BSMAF 1818

Norway's Siem Offshore to be largest shareholder of Daya Materials

Siem Offshore recorded an additional impairment of US$19mil against its receivables from Daya in its company’s annual accounts for 2017.

KL shares open lower

2018-03-15 themalaymailonline
KUALA LUMPUR, March 15 — Shares on Bursa Malaysia opened lower this morning in tracking Wall Street’s under performance, coupled with traders taking a risk aversion-stance, dealers said.
0154 0025 PBLOF 5225 0091 Q0F 1295 BSMAF 1481 IHHHF 1818

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

5h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...